Minimal dose CT superior to chest X-ray for detection of recurrent lung cancer

Greater sensitivity, with lower radiation dose, allows for faster treatment, reported at 93rd AATS Annual Meeting

2013-05-06

(Press-News.org) Minneapolis, MN, May 6, 2013 – Lung cancer is associated with very high mortality, in part because it is hard to detect at early stages, but also because it can recur frequently after surgical removal. The question arises as to what is the best way to follow lung cancer patients after surgery in order to spot problems early enough, before symptoms become obvious, so that patients may still be eligible for new interventions. In this study presented at the 93rd AATS Annual Meeting, investigators from the University of Toronto departments of Thoracic Surgery and Diagnostic Radiology show that minimal dose computed tomography (MnDCT) of the thorax offers much greater sensitivity at detecting new or recurrent lung cancer, with equivalent amount of radiation, compared to conventional chest x-rays.

"Up to a few years ago, we were using chest x-rays to monitor patients after surgery for lung cancer, but this follow-up was ineffective, and many patients still died of recurrent lung cancer, comments lead investigator Waël C. Hanna, MDCM, MBA, of the Department of Thoracic Surgery at the University of Toronto. "While CT scans can effectively be used to monitor lung cancer after surgery, there was significant concern about the large amount of radiation that will be delivered to patients, and standard dose CT scans were not used routinely in the follow-up of lung cancer. More recently, new technology allowed us to develop MnDCT."

As reported in this study, the majority of new or recurrent cancer was detected by MnDCT at a subclinical, intrathoracic stage, within two years of surgery. This allowed for the delivery of curative treatment in the majority of patients with asymptomatic cancer and was associated with long survival.

The study followed 271 patients with lung cancer (80% Stage I, 12.5% Stage II) who underwent curative resection of lung cancer. Repeated imaging occurred at 3, 6, 12, 18, 24, 36, 48 and 60 months using both standard chest x-rays and MnDCT.

Investigators found that MnDCT detected 94% of recurrent cancers compared to only 21% with standard x-rays (p END

ELSE PRESS RELEASES FROM THIS DATE:

Low-dose anticoagulation therapy used with new design mechanical heart valve lowers bleeding risk

2013-05-06

Minneapolis, MN, May 6, 2013 – For more than 40 years, patients under 65 years of age requiring heart valve replacement have had to choose between a mechanical valve that offers life-long durability but requires aggressive warfarin anticoagulation or a biological (cow or pig) valve that will wear out in 10-20 years but does not require anticoagulation. Aggressive warfarin anticoagulation is accompanied by significant annual risk of bleeding, while inadequate anticoagulation of a mechanical artificial valve has been associated with high risk of clotting problems that can ...

Activity of cancer inducing genes can be controlled by the cell's skeleton

2013-05-06

Cancer is a complex disease, in which cells undergo a series of alterations, including changes in their architecture; an increase in their ability to divide, to survive and to invade new tissues or metastasis. A category of genes, called oncogenes, is critical during cancer progression, as they codify proteins whose activity favours the development of cancer. One of these molecules, Src, is implicated in a large number of human cancers. However, it is still not clear how healthy cells constrain its activity not to become tumorous. In the latest issue of the journal Oncogene*, ...

Progerin's 'discrimination' may contribute to fatal disease HGPS

2013-05-06

A mutant protein responsible for Hutchinson-Gilford Progeria syndrome (HGPS) bars large proteins from entering the nucleus, according to a study in The Journal of Cell Biology. The culprit in HGPS, a fatal disease that resembles premature aging, is a protein variant called Progerin. This defective protein impairs cells in many ways, including reducing nuclear levels of the RanGTPase. Ran is crucial for nuclear import and export, as it stimulates unloading of cargo that has just entered the nucleus and loading of cargo that's ready to exit. Progerin also impedes the import ...

Wip1 could be new target for cancer treatment

2013-05-06

Researchers have uncovered mutations in the phosphatase Wip1 that enable cancer cells to foil the tumor suppressor p53, according to a study in The Journal of Cell Biology. The results could provide a new target for the treatment of certain cancers. Like a battlefield surgeon who has to decide which casualties can be saved, p53 performs triage on cells with injured DNA. If the damage is serious, p53 spurs the cells to die or stop proliferating. But after milder hits, p53 activates a DNA damage response (DDR) mechanism, which instigates repairs, and temporarily prevent ...

New Canadian guidelines for treating fibromyalgia

2013-05-06

Physicians from the McGill University Health Centre (MUHC) and the University of Calgary have published a review article in the CMAJ (Canadian Medical Association Journal) to help family doctors diagnose and treat fibromyalgia. The article represents the first time researchers have published Canadian guidelines to help manage the condition. Fibromyalgia is a chronic condition that affects the central nervous system causing pain throughout the body. It is often accompanied by fatigue, depression and sleep problems. It affects mostly women and their multiple symptoms ...

Ubiquitous engineered nanomaterials cause lung inflammation, study finds

2013-05-06

(SACRAMENTO, Calif.) -- A consortium of scientists from across the country has found that breathing ultrafine particles from a large family of materials that increasingly are found in a host of household and commercial products, from sunscreens to the ink in copy machines to super-strong but lightweight sporting equipment, can cause lung inflammation and damage. The research on two of the most common types of engineered nanomaterials is published online today in Environmental Health Perspectives, the journal of the National Institute of Environmental Health Sciences (NIEHS). ...

LCSB discovers endogenous antibiotic in the brain

2013-05-06

Luxembourg, 6 May 2013 – Scientists from the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have discovered that immune cells in the brain can produce a substance that prevents bacterial growth: namely itaconic acid. Until now, biologists had assumed that only certain fungi produced itaconic acid. A team working with Dr. Karsten Hiller, head of the Metabolomics Group at LCSB, and Dr. Alessandro Michelucci has now shown that even so-called microglial cells in mammals are also capable of producing this acid. "This is a ground breaking result," ...

Schools may help close gap to mental health services for adolescents with mental disorders

2013-05-06

Washington D.C., May 6, 2013 – A study published in the May 2013 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found that mental health resources provided by schools are significantly associated with whether adolescents with mental disorders receive needed mental health services. In particular, adolescents with disorders attending schools that engage in early identification of emotional problems, are significantly more likely to receive mental health services. Using data from the National Comorbidity Survey Replication Adolescent Supplement ...

Reversal of the black widow myth

2013-05-06

VIDEO: Reverse cannibalism: Some male spiders prefer to eat old females rather than mate with them. Click here for more information. The Black Widow spider gets its name from the popular belief that female spiders eat their male suitors after mating. However, a new study has shown that the tendency to consume a potential mate is also true of some types of male spider. The study by Lenka Sentenska and Stano Pekar from Masaryk University in the Czech Republic finds that male ...

Possible treatment for serious blood cancer

2013-05-06

A single antibody could be the key to treating multiple myeloma, or cancer of the blood, currently without cure or long-term treatment. "We tested the antibody in various ways, including on tumour cells from myeloma patients that have been transplanted into mice. The tests showed that the antibody is able to destroy myeloma cells", explains Markus Hansson, a researcher at Lund University in Sweden. Using a 'biological library' of thousands of antibodies from the company BioInvent in Lund, the team singled out antibody BI-505, shown to have a powerful effect on the ...